Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options

• Váldodahkkit: Amirah Azzeri (Dahkki), Maznah Dahlui (Dahkki), Rosmawati Mohamed (Dahkki), Scott Alexander McDonald (Dahkki), Hafiz Jaafar (Dahkki), Fatiha Hana Shabaruddin (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

IntroductionA scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia. Recently, limited access to sofosbuvir/daclatasvir (SOF/DAC) is available through compulsory licensing, with access to...